{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-196475","form_type":"8-K","ticker":"RPRX","cik":"0001802768","company_name":"Royalty Pharma plc","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.572951+00:00","generated_at":"2026-05-31T11:08:28.413283+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Royalty Pharma Q2 Portfolio Receipts $608M (+12% YoY); raises FY 2024 guidance to $2.7-2.775B","bullets":["Royalty Receipts grew 11% to $605M, driven by cystic fibrosis franchise, Trelegy (+32%), Tremfya (+34%), and Evrysdi (+91%).","Raised FY 2024 Portfolio Receipts guidance: $2,700M-$2,775M (previous $2,600M-$2,700M), implying 9-12% Royalty Receipts growth.","Capital deployed ~$2B YTD including $905M for Voranigo (approved Aug 6) and $575M expanded Cytokinetics collaboration.","Issued $1.5B senior notes at 5.5% in June; total debt $7.8B at 3.1% avg cost; repurchased 4M shares for $115M YTD.","Trodelvy Phase 3 TROPiCS-04 failed survival endpoint; BioCryst discontinued BCX10013 – potential portfolio headwinds."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-196475","json":"https://secwatch.observer/filing/0001193125-24-196475.json","markdown":"https://secwatch.observer/filing/0001193125-24-196475.md","text":"https://secwatch.observer/filing/0001193125-24-196475.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802768/000119312524196475/0001193125-24-196475-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802768/000119312524196475/d857022d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:08:28.413283+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}